SHERIDAN, WYOMING – November 9, 2024 – Varian Medical Systems, a Siemens Healthineers company, is proud to showcase its innovative TrueBeam® radiotherapy system, a cutting-edge technology designed to revolutionize cancer treatment. TrueBeam integrates hardware, software, treatment regimens, and safety features to provide clinicians with the tools they need to deliver precise and effective radiation therapy.    

"Advances in radiation therapy are accelerating, creating new options for treatment and new sources of optimism in the fight against cancer," says Varian Medical Systems.    

TrueBeam's comprehensive capabilities enable clinicians to focus on patients and treatments rather than systems and technologies. The system's integrated imaging system allows for improved soft tissue target visualization and faster cone-beam CT (CBCT) acquisitions, facilitating breath-hold treatments.

SHERIDAN, WYOMING – November 9, 2024 – Terumo Corporation (TSE: 4543) today announced a series of strategic leadership appointments to further strengthen its global operations and drive continued innovation in medical technology. The changes, effective October 1, 2024, included key positions within the Cardiac and Vascular Company and Terumo Americas Holding, Inc.

New Leadership Appointments

Fumihisa Hirose was promoted to Group Managing Executive Officer and President of the Cardiac and Vascular Company.  Mr. Hirose previously served as President of the Cardiac and Vascular Company and Division President of the Interventional Systems Division.

Ghada Farah was appointed as Division President of the Interventional Systems Division within the Cardiac and Vascular Company. Ms. Farah brought extensive experience to this role, having previously served as Senior Vice President for EMEA in the Interventional Systems Division at Terumo Europe N.V.

SHERIDAN, WYOMING – November 9, 2024 – In a move set to transform blood processing in the United States, Terumo Blood and Cell Technologies (Terumo BCT) has launched the Reveos™ Automated Blood Processing System.  This innovative technology, already used in over 50 countries for more than a decade, promises to significantly enhance efficiency and address critical platelet shortages.

"Reveos is a revolutionary technology that automates whole blood processing. By streamlining the process, it significantly improves efficiency and consistency compared to traditional manual methods used by U.S. blood centers," says Chetan Makam, General Manager, Global Blood Solutions, Terumo BCT. "It's a new way to be more efficient for blood centers, for processing whole blood into its components including platelets. Reveos will help blood centers do more with the blood donors already walking through the doors."

SHERIDAN, WYOMING – November 9, 2024 – Terumo Corporation, a leading medical technology company, has raised its financial forecast for the fiscal year ending March 31, 2025. This comes on the heels of impressive first-half results and favorable shifts in foreign exchange rates.

The company now anticipates consolidated revenue of 1.01 trillion yen, a 30 billion yen increase from its previous estimate. This upward revision reflects better-than-expected revenue in the first and second quarters, coupled with the yen's depreciation exceeding initial projections.

"Terumo's strong performance is fueled by robust growth across its various business segments, including Cardiac and Vascular, General Hospital, and Blood and Cell Technologies," said a company spokesperson. "The company's innovative products and global presence have allowed it to effectively meet the growing worldwide demand for healthcare solutions."

SHERIDAN, WYOMING – November 9, 2024 – Novartis, a global healthcare company, recently released promising data on its  Kesimpta® (ofatumumab) treatment for relapsing multiple sclerosis (RMS).  The findings, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting, highlight the long-term benefits of Kesimpta for both first-line and switch patients.

Relapsing multiple sclerosis is a chronic disease that affects the central nervous system, disrupting the flow of information within the brain, and between the brain and body.  It is characterized by periods of relapse (disease activity) and remission (recovery).  Kesimpta is a targeted B-cell therapy that works by reducing the number of B-cells, a type of immune cell thought to play a key role in MS attacks.

Kesimpta Demonstrates Sustained Efficacy in Preventing Disability Progression

SHERIDAN, WYOMING – November 9, 2024 – Novartis, a global healthcare leader, has announced exciting news from its Phase III APPLAUSE-IgAN study. Iptacopan, an investigational oral medication, has demonstrated significant potential in treating IgA nephropathy (IgAN), a rare and progressive kidney disease. This breakthrough offers renewed hope for young adults living with this challenging condition.

Understanding IgA Nephropathy

IgAN, often diagnosed in young adults, is a complex autoimmune disease where the body's immune system mistakenly attacks the kidneys. This leads to inflammation and damage, potentially resulting in kidney failure. Current treatments have limitations in addressing the root cause of the disease, highlighting the urgent need for more effective therapies.

Iptacopan: A New Approach to Treatment

SHERIDAN, WYOMING – November 9, 2024 – SHERIDAN, WYOMING – November 9, 2024 – When it comes to contact lens wear, open communication between eye care providers and patients is essential for achieving lasting satisfaction and optimal eye health. Alcon, a global leader in eye care, recognizes the importance of this relationship and emphasizes the value of in-depth discussions to address patient needs and concerns.

Understanding Patient Priorities

Eye care professionals (ECPs) need to understand what patients look for most in their contact lenses. Comfort is often a top priority, and patients need a safe space to discuss any discomfort they experience with their current lenses.

Research indicates that a significant percentage of patients hesitate to discuss comfort issues with their ECPs. Some patients may feel embarrassed or believe that discomfort is a normal part of wearing contact lenses.

SHERIDAN, WYOMING – November 9, 2024 – In a significant advancement for healthcare diagnostics, bioMérieux, a world leader in in vitro diagnostics, announces the launch of VIDAS® VITAMIN B12 TOTAL, a groundbreaking automated test designed to revolutionize the detection and management of vitamin B12 deficiency. This innovative test, which received CE marking, offers a rapid and efficient method for measuring vitamin B12 concentration in human serum or plasma, providing healthcare professionals with a critical tool for accurate diagnosis and timely treatment.

SHERIDAN, WYOMING – November 9, 2024 – SHERIDAN, WYOMING – November 9, 2024 – Alcon, a global leader in eye care dedicated to helping people see brilliantly, presented its latest innovations and clinical data at the American Academy of Ophthalmology (AAO) 2024 annual meeting. The company showcased advancements in glaucoma therapy, retina surgery, and dry eye treatment, demonstrating its commitment to improving patient outcomes and streamlining surgical workflows.

Voyager™ DSLT: Revolutionizing Glaucoma Treatment

Alcon's latest innovation for glaucoma therapy, the Voyager™ Direct Selective Laser Trabeculoplasty (DSLT) device, was a highlight of the event. This groundbreaking technology offers a first-line treatment option for glaucoma patients, eliminating the need for a gonio lens or manual aiming required for traditional Selective Laser Trabeculoplasty (SLT).

SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline.  The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development.

Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.

Dupixent Continues its Impressive Growth Trajectory